You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News and reporting on lung cancer.
The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.
The new guidelines said ROS1, KRAS, BRAF, MET, RET, and HER2 should be included in targeted and expanded panels.
Under the deal, Hong Kong-based Genostics will have the exclusive rights to manufacture and distribute EarlyCDT products in China.
One firm, Exosome Diagnostics, is working to streamline payor coverage for a commercial test, and researchers are simultaneously developing promising ways to isolate exosomes.
The firm's blood-based Epi proLung lung cancer test looks for a combination of DNA methylation biomarkers.
With Medicare coverage for the test in place, the company is hoping it will surpass the limited commercial success of its initial Xpresys Lung offering.
Labs reported on their work with kits from both Roche and Thermo Fisher, both of which have launched new commercial liquid biopsy products in recent years.
The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.
The partners plan to validate blood-based microRNAs as biomarkers for the early detection of pulmonary and neurodegenerative diseases.
Veracyte attributed its lower Afirma sales in part to slowing down the rollout of an updated version of the test that relies on RNA sequencing.